Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;6(10):864-873.
doi: 10.1016/S2468-1253(21)00183-7. Epub 2021 Aug 6.

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

Affiliations
Review

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

Mohammed Eslam et al. Lancet Gastroenterol Hepatol. 2021 Oct.

Abstract

The term non-alcoholic fatty liver disease (NAFLD), and its definition, have limitations for both adults and children. The definition is most problematic for children, for whom alcohol consumption is usually not a concern. This problematic definition has prompted a consensus to rename and redefine adult NAFLD associated with metabolic dysregulation to metabolic (dysfunction)-associated fatty liver disease (MAFLD). Similarities, distinctions, and differences exist in the causes, natural history, and prognosis of fatty liver diseases in children compared with adults. In this Viewpoint we, an international panel, propose an overarching framework for paediatric fatty liver diseases and an age-appropriate MAFLD definition based on sex and age percentiles. The framework recognises the possibility of other coexisting systemic fatty liver diseases in children. The new MAFLD diagnostic criteria provide paediatricians with a conceptual scaffold for disease diagnosis, risk stratification, and improved clinical and multidisciplinary care, and they align with a definition that is valid across the lifespan.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JG reports personal fees from Gilead, Pfizer, AstraZeneca, Pharmaxis, Cincera, Novartis, Roche, Intercept, Novo, and MSD during the writing of the report. LAB reports personal fees from Novo Nordisk. CM reports personal fees from Evira and Itrim, and grants and personal fees from Novo Nordisk. ME reports personal fees from Pfizer. The other authors declare no competing interests.

Comment in

Publication types

MeSH terms

LinkOut - more resources